Skip to main content
SLU publication database (SLUpub)
Research article - Peer-reviewed, 2022

An inverse association between plasma benzoxazinoid metabolites and PSA after rye intake in men with prostate cancer revealed with a new method

Nordin, Elise; Steffensen, Stine K.; Laursen, Bente B.; Andersson, Sven-Olof; Johansson, Jan-Erik; Aman, Per; Hallmans, Goran; Borre, Michael; Staerk, Dan; Hanhineva, Kati; Fomsgaard, Inge S.; Landberg, Rikard

Abstract

Prostate cancer (PC) is a common cancer among men, and preventive strategies are warranted. Benzoxazinoids (BXs) in rye have shown potential against PC in vitro but human studies are lacking. The aim was to establish a quantitative method for analysis of BXs and investigate their plasma levels after a whole grain/bran rye vs refined wheat intervention, as well as exploring their association with PSA, in men with PC. A quantitative method for analysis of 22 BXs, including novel metabolites identified by mass spectrometry and NMR, was established, and applied to plasma samples from a randomized crossover study where patients with indolent PC (n = 17) consumed 485 g whole grain rye/rye bran or fiber supplemented refined wheat daily for 6 wk. Most BXs were significantly higher in plasma after rye (0.3-19.4 nmol/L in plasma) vs. refined wheat (0.05-2.9 nmol/L) intake. HBOA-glc, 2-HHPAA, HBOA-glcA, 2-HPAA-glcA were inversely correlated to PSA in plasma (p < 0.04). To conclude, BXs in plasma, including metabolites not previously analyzed, were quantified. BX metabolites were significantly higher after rye vs refined wheat consumption. Four BX-related metabolites were inversely associated with PSA, which merits further investigation.

Published in

Scientific Reports
2022, Volume: 12, article number: 5260
Publisher: NATURE PORTFOLIO

    UKÄ Subject classification

    Nutrition and Dietetics
    Clinical Laboratory Medicine

    Publication identifier

    DOI: https://doi.org/10.1038/s41598-022-08856-z

    Permanent link to this page (URI)

    https://res.slu.se/id/publ/116837